Hydrogen peroxide (Eskata): Difference between revisions

Jump to navigation Jump to search
← Older editNewer edit →
VisualWikitext
Sonya Gelfand (talk | contribs)
nocaptcha
1,056 edits
No edit summary
Sonya Gelfand (talk | contribs)
nocaptcha
1,056 edits
No edit summary
Line 245: Line 245:
(Description)
(Description)
|drugBox={{Drugbox2
|drugBox={{Drugbox2
| verifiedrevid =  
| Verifiedimages = changed
| IUPAC_name =  
| Watchedfields = changed
| image =  
| verifiedrevid = 477315142
| drug_name =  
| Name = Hydrogen peroxide
 
| ImageFileL1_Ref = {{chemboximage|correct|??}}
<!--Clinical data-->
| ImageFile =  
| tradename =  
| ImageFileL1 = h2o2pic.png
| MedlinePlus =
| ImageNameL1 = Structural formula of hydrogen peroxide
| licence_US =
| ImageFileR1 = Hydrogen-peroxide-3D-vdW.png
| pregnancy_AU =  
| ImageNameR1 = space filling model of the hydrogen peroxide molecule
| pregnancy_US =  
| IUPACName = Hydrogen peroxide
| legal_status =  
| OtherNames = Dioxidane<br />Oxidanyl<br />Perhydroxic acid<br />0-hydroxyol<br />Dihydrogen dioxide
| routes_of_administration =
| SystematicName =  
 
| Section1 = {{Chembox Identifiers
<!--Pharmacokinetic data-->
| UNII_Ref = {{fdacite|correct|FDA}}
| bioavailability =  
| UNII = BBX060AN9V
| metabolism =  
| KEGG_Ref = {{keggcite|correct|kegg}}
| elimination_half-life =  
| KEGG = D00008
| excretion =
| InChI = 1/H2O2/c1-2/h1-2H
 
| ChEBI_Ref = {{ebicite|correct|EBI}}
<!--Identifiers-->
| ChEBI = 16240
| CAS_number_Ref =  
| SMILES = OO
| CAS_number =  
| InChIKey = MHAJPDPJQMAIIY-UHFFFAOYAL
| ATC_prefix =  
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ATC_suffix =  
| ChEMBL = 71595
| PubChem =  
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| IUPHAR_ligand =  
| StdInChI = 1S/H2O2/c1-2/h1-2H
| DrugBank_Ref =  
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| DrugBank =  
| StdInChIKey = MHAJPDPJQMAIIY-UHFFFAOYSA-N
| ChemSpiderID_Ref =  
| CASNo = 7722-84-1
| ChemSpiderID =  
| CASNo_Ref = {{cascite|correct|CAS}}
| UNII_Ref =  
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| UNII =  
| ChemSpiderID = 763
| KEGG_Ref =  
| PubChem = 784
| KEGG =  
| IUPHAR_ligand = 2448
| ChEBI_Ref =  
| RTECS = MX0900000 (>90% soln.)<br />MX0887000 (>30% soln.)
| ChEBI =  
| EINECS = 231-765-0
| ChEMBL_Ref =  
| UNNumber = 2015 (>60% soln.)<br />2014 (20–60% soln.)<br />2984 (8–20% soln.)
| ChEMBL =  
 
<!--Chemical data-->
| C= | H= | N= | O=
| molecular_weight =  
| smiles =
| InChI =
| InChIKey =  
| StdInChI_Ref =  
| StdInChI =  
| StdInChIKey_Ref =  
| StdInChIKey =  
| melting_point =  
}}
}}
|mechAction=(Description)
|mechAction=
|structure=(Description with picture)
*The mechanism of action for hydrogen peroxide for the treatment of seborrheic keratosis is unknown.
|PD=(Description)
|structure=
|PK=(Description)
[[image:h2o2structure.png|none|thumb|400px|This image is provided by the National Library of Medicine.]]
|nonClinToxic=(Description)
|PD=
*The pharmacodynamics of hydrogen peroxide in the treatment of seborrheic keratosis are unknown.
|PK=
*Following application of hydrogen peroxide in patients with seborrheic keratosis lesions, hydrogen peroxide rapidly dissociates into water and reactive oxygen species. Indirect assessment of reactive oxygen species in patients with seborrheic keratosis lesions did not demonstrate any systemic absorption of hydrogen peroxide.
|nonClinToxic=
=====Carcinogenesis, Mutagenesis, Impairment of Fertility=====
*Long-term animal studies have not been performed to evaluate the carcinogenic potential of hydrogen peroxide.
*Hydrogen peroxide has been found to exhibit positive results in in vitro tests for genotoxicity, but has not exhibited positive results in in vivo tests for genotoxicity, presumably due to the rapid metabolism of hydrogen peroxide.
*The effects of hydrogen peroxide on fertility have not been evaluated. Hydrogen peroxide has been associated with effects on sperm function and elevated testicular hydrogen peroxide concentration has been implicated in male infertility, although in vivo, no effect of hydrogen peroxide on sperm function has been demonstrated.
|clinicalStudies=
|clinicalStudies=
*In two double-blind, vehicle-controlled clinical trials, 937 subjects with 4 clinically typical seborrheic keratoses that are raised on the face, trunk, or extremities were randomized to treatment with either ESKATA or vehicle. Subjects ranged from 42 to 91 years of age (mean 68.7 years), 58% percent were female, and 98% were Caucasian. A total of 925 subjects completed the trials. Each lesion was treated with 4 applications, at baseline and again at Day 22, if needed, and subjects were followed through Day 106.
*In two double-blind, vehicle-controlled clinical trials, 937 subjects with 4 clinically typical seborrheic keratoses that are raised on the face, trunk, or extremities were randomized to treatment with either ESKATA or vehicle. Subjects ranged from 42 to 91 years of age (mean 68.7 years), 58% percent were female, and 98% were Caucasian. A total of 925 subjects completed the trials. Each lesion was treated with 4 applications, at baseline and again at Day 22, if needed, and subjects were followed through Day 106.

Revision as of 16:17, 16 July 2018

{{DrugProjectFormSinglePage |authorTag= Sonya Gelfand |genericName=generic name |aOrAn=a |drugClass=Acetylcholine release inhibitor, Adrenergic receptor agonist |indicationType=(type of indication of drug) |indication=a list of indications, separated by commas. |hasBlackBoxWarning=Yes |adverseReactions=a list of adverse reactions, separated by commas. |blackBoxWarningTitle=Warning Title |blackBoxWarningBody=Condition Name: (Content) |fdaLIADAdult======Condition 1=====

  • Dosing Information
  • (Dosage)
Condition 2
  • Dosing Information
  • (Dosage)

|offLabelAdultGuideSupport======Condition 1=====

  • Developed by: (Organisation)
  • Class of Recommendation: (Class) (Link)
  • Strength of Evidence: (Category A/B/C) (Link)
  • Dosing Information/Recommendation
  • (Dosage)
Condition 2
  • Developed by: (Organisation)
  • Class of Recommendation: (Class) (Link)
  • Strength of Evidence: (Category A/B/C) (Link)
  • Dosing Information/Recommendation
  • (Dosage)

|offLabelAdultNoGuideSupport======Condition 1=====

  • Dosing Information
  • (Dosage)
Condition 2
  • Dosing Information
  • (Dosage)
Condition 3
  • Dosing Information
  • (Dosage)

|fdaLIADPed======Condition 1=====

  • Dosing Information
  • (Dosage)
Condition 2
  • Dosing Information
  • (Dosage)

|offLabelPedGuideSupport======Condition 1=====

  • Developed by: (Organisation)
  • Class of Recommendation: (Class) (Link)
  • Strength of Evidence: (Category A/B/C) (Link)
  • Dosing Information/Recommendation
  • (Dosage)
Condition 2
  • Developed by: (Organisation)
  • Class of Recommendation: (Class) (Link)
  • Strength of Evidence: (Category A/B/C) (Link)
  • Dosing Information/Recommendation
  • (Dosage)

|offLabelPedNoGuideSupport======Condition 1=====

  • Dosing Information
  • (Dosage)
Condition 2
  • Dosing Information
  • (Dosage)
Condition 3
  • Dosing Information
  • (Dosage)

|contraindications=CONTRAINDICATIONS |warnings======Conidition 1=====

(Description)

Conidition 2

(Description)

Conidition 3

(Description) |clinicalTrials=======Central Nervous System======

(list/description of adverse reactions)
Cardiovascular
(list/description of adverse reactions)
Respiratory
(list/description of adverse reactions)
Gastrointestinal
(list/description of adverse reactions)
Hypersensitive Reactions
(list/description of adverse reactions)
Miscellaneous
(list/description of adverse reactions)
Condition 2
Central Nervous System
(list/description of adverse reactions)
Cardiovascular
(list/description of adverse reactions)
Respiratory
(list/description of adverse reactions)
Gastrointestinal
(list/description of adverse reactions)
Hypersensitive Reactions
(list/description of adverse reactions)
Miscellaneous
(list/description of adverse reactions)

|postmarketing=(Description) |drugInteractions=* Drug 1

  • Drug 2
  • Drug 3
  • Drug 4
  • Drug 5
Drug 1

(Description)

Drug 2

(Description)

Drug 3

(Description)

Drug 4

(Description)

Drug 5

(Description) |useInPregnancyFDA=(Description) |useInLaborDelivery=(Description) |useInNursing=(Description)g |useInPed=(Description) |useInGeri=(Description) |useInGender=(Description) |useInRace=(Description) |useInRenalImpair=(Description) |useInHepaticImpair=(Description) |useInReproPotential=(Description) |useInImmunocomp=(Description) |othersTitle=Others |useInOthers=(Description) |administration=(Oral/Intravenous/etc) |monitoring======Condition 1=====

(Description regarding monitoring, from Warnings section)

Condition 2

(Description regarding monitoring, from Warnings section)

Condition 3

(Description regarding monitoring, from Warnings section)

|overdose====Acute Overdose===

Signs and Symptoms

(Description)

Management

(Description)

Chronic Overdose

Signs and Symptoms

(Description)

Management

(Description) |drugBox=

Hydrogen peroxide (Eskata)
Systematic (IUPAC) name
?
Identifiers
CAS number ?
ATC code ?
PubChem ?
Chemical data
Formula ?
Mol. mass ?
Pharmacokinetic data
Bioavailability ?
Metabolism ?
Half life ?
Excretion ?
Therapeutic considerations
Pregnancy cat.

?

Legal status
Routes ?

Retrieved from "https://www.wikidoc.org/index.php?title=Hydrogen_peroxide_(Eskata)&oldid=1482698"